Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 5/2013

01-05-2013 | Research Article

Circulating autoantibody to ABCC3 may be a potential biomarker for esophageal squamous cell carcinoma

Authors: Y. Cheng, J. Xu, J. Guo, Y. Jin, X. Wang, Q. Zhang, L. Liu

Published in: Clinical and Translational Oncology | Issue 5/2013

Login to get access

Abstract

Purpose

There is an urgent need to identify biomarkers for early diagnosis and prognosis of esophageal cancer. The present study was undertaken to test whether circulating autoantibodies to ATP-binding cassette C3 (ABCC3) transporter could serve as a biomarker for the malignant tumor.

Methods

An enzyme-linked immunosorbent assay approach was developed in-house to test circulating autoantibodies to ABCC3 in 114 patients with esophageal squamous cell carcinoma (ESCC) and 226 healthy subjects well matched in age and smoking history.

Results

Mann–Whitney U test showed that the IgA antibody levels were significantly higher in patients with ESCC than control subjects (Z = −4.226, P < 0.001) while the IgG antibody levels were not significantly different between the two groups (Z = −1.072, P = 0.284). The sensitivity against >95 % specificity was 13.2 % for the IgA assay with an inter-assay deviation of 13.0 and 7.9 % for the IgG assay with an inter-assay deviation of 9.4 %.

Conclusions

This work suggests that circulating IgA autoantibody to ABCC3 may be a potential biomarker for ESCC, which could be used for early diagnosis and prognosis of the malignant tumor.
Literature
1.
2.
Lam KY, Ma L (1997) Pathology of esophageal cancers: local experience and current insights. Chin Med J (Eng) 110:459–464
3.
Polednak AP (2003) Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. Int J Cancer 105:98–100PubMedCrossRef
4.
Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, Barnes A, Robertson J (2007) Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 18:868–873PubMedCrossRef
5.
Tan HT, Low J, Lim SG (2009) Serum autoantibodies as biomarkers for early cancer detection. FEBS J 276:6880–6904PubMedCrossRef
6.
Ranju R, Arora S, Chattopadhyay TK, Shukla NK, Mathur M (2000) Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer 86:791–795
7.
Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, Kobayashi S, Ochiai T (2000) Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 89:1677–1683PubMedCrossRef
8.
Fujita Y, Nakanishi T, Hiramatsu M, Mabuchi H, Miyamoto Y, Miyamoto A, Shimizu A, Tanigawa N (2006) Proteomics based approach identifying autoantibody against Peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. FEBS J 12:6415–6420
9.
Fujita Y, Nakanishi T, Miyamoto Y, Hiramatsu M, Mabuchi H, Miyamoto A, Shimizu A, Takubo T, Tanigawa N (2008) Protemics based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett 263:280–290PubMedCrossRef
10.
11.
Zhou J-H, Zhang B, Kernstine KH, Zhong L (2011) Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma. World J Gastroenterol 17:1373–1378PubMedCrossRef
12.
Gatti L, Cossa G, Beretta GL, Zaffaroni N, Perego P (2011) Novel insights into targeting ATP-binding cassette transporters for antitumor therapy. Curr Med Chem 18:4237–4249PubMedCrossRef
13.
Calcagno AM, Ambudkar SV (2010) Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells. Methods Mol Biol 596:77–93PubMedCrossRef
14.
Marzac C, Garrido E, Tang R, Fava F, Hirsch P, De Benedictis C, Corre E, Lapusan S, Lallemand JY, Marie JP, Jacquet E, Legrand O (2011) ATP binding cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients. Haematologica 96:1293–1301PubMedCrossRef
15.
Partanen L, Staaf J, Tanner M, Tuominen VJ, Borg A, Isola J (2012) Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer. Genes Chromosomes Cancer 51:832–840PubMedCrossRef
16.
17.
Söllner J, Heinzel A, Summer G, Fechete R, Stipkovits L, Szathmary S, Mayer B (2010) Concept and application of a computational vaccinology workflow. Immunome Res 6(suppl 2):S7PubMedCrossRef
18.
Liu L, Liu N, Liu B, Yang Y, Zhang Q, Zhang W, Yu P, Jin Y, Guo J, Guan S, Sun S, Miao L, Wei J (2012) Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer? J Cancer Res Clin Oncol 138:1737–1742PubMedCrossRef
19.
Mayerhofer K, Tempfer C, Kucera E, Hefler L, Zeisler H, Kainz C, Zeillinger R, Sliutz G (1999) Humoral p53 antibody response is a prognostic parameter in ovarian cancer. Anticancer Res 19:875–878PubMed
20.
Abendstein B, Daxenbichler G, Windbichler G, Zeimet AG, Geurts A, Sweep F, Marth C (2000) Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients. Anticancer Res 20:569–572PubMed
21.
Reuschenbach M, von Knebel Doeberitz M, Wentzensen N (2009) A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 58:1535–1544PubMedCrossRef
22.
Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94:1914–1918PubMedCrossRef
23.
Weber-Mzell D, Kotanko P, Hauer AC, Goriup U, Haas J, Lanner N, Erwa W, Ahmaida IA, Haitchi-Petnehazy S, Stenzel M, Lanzer G, Deutsch J (2004) Gender, age and seasonal effects on IgA deficiency: a study of 7293 Caucasians. Eur J Clin Invest 34:224–228PubMedCrossRef
Metadata
Title
Circulating autoantibody to ABCC3 may be a potential biomarker for esophageal squamous cell carcinoma
Authors
Y. Cheng
J. Xu
J. Guo
Y. Jin
X. Wang
Q. Zhang
L. Liu
Publication date
01-05-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 5/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0941-9

Other articles of this Issue 5/2013

Clinical and Translational Oncology 5/2013 Go to the issue

Brief Research Article

Expression analysis of tumor-related genes involved in critical regulatory pathways in schwannomas

Erratum

Erratum to: Polymorphisms in HIF-1alpha affect presence of lymph node metastasis and can influence tumor size in squamous-cell carcinoma of the glottic larynx

Research Article

Dose–volume histogram parameters for predicting radiation pneumonitis using receiver operating characteristic curve

Brief Research Article

Cone-beam computed tomography dose monitoring during intensity-modulated radiotherapy in head and neck cancer: parotid glands

Educational Series – Blue Series

MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications

Educational Series - Blue Series

Polymorphisms in HIF-1alpha affect presence of lymph node metastasis and can influence tumor size in squamous-cell carcinoma of the glottic larynx
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits